Can I ask my doctor for Mounjaro — and what happens if I do?

What asking your GP actually means in 2025/26

Bringing up Mounjaro with your GP is a sensible first step, but it helps to know what they can and can't do before you walk in. On the NHS, tirzepatide became prescribable in primary care from 1 April 2026 under the new GP contract, but participation is optional. Some practices have signed up; many haven't. Even where they have, the eligibility criteria are strict: NICE's guidance (TA1026) sets the current NHS threshold at a BMI of 40 or above, with four or more qualifying conditions from a defined list that includes high blood pressure, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea and cardiovascular disease.

That is a narrow group. If you don't sit within it, your GP may be genuinely supportive but simply unable to prescribe under NHS rules. They might suggest you look at private routes, or refer you to a specialist weight management service for semaglutide (Wegovy) under NICE TA875. Understanding this before the appointment means you won't mistake a 'not on the NHS' answer for 'this medicine isn't right for you'. The two things are not the same.

NHS England's guidance on weight management injections sets out the phased rollout clearly if you want to check the thresholds in full before your appointment.

How to frame the conversation, and what your GP will need to consider

If you've decided to raise it, being direct helps. You don't need to arrive with a printed clinical trial. Saying something like "I've been reading about tirzepatide for weight management and I'd like to know whether it's something you can prescribe, or what my options are" gives your GP enough to work with. They'll look at your BMI, any relevant health conditions, your medication list and your history, because those factors all shape whether Mounjaro is appropriate for you specifically.

A few things your GP will consider: whether you have contraindications such as a history of pancreatitis or certain thyroid conditions; whether other medicines you take could interact; and, if the NHS route is on the table, whether your practice is participating in the scheme. They may also ask about previous attempts at weight management. None of this is obstructive, it's the clinical assessment that any legitimate prescription requires. Our guide to doctors and Mounjaro prescriptions covers the clinical picture in more detail if you want to prepare.

One practical note: GP appointments are short. If you want a proper discussion about Mounjaro specifically, booking a longer slot and mentioning the reason in advance gives both you and your doctor more time to go through it properly.

What happens if your GP can't prescribe it, or you'd rather not wait

This is where many people find themselves. Your GP may be supportive but not yet set up to prescribe tirzepatide under the NHS contract, or you may not meet the current NHS thresholds despite having a clear clinical need. In that situation, a regulated private route is the practical alternative.

A GPhC-registered online pharmacy with its own Independent Prescribers can carry out a full clinical assessment and, if you're suitable, issue a private prescription on the same day. The private eligibility criteria broadly follow the licensed indications in the Mounjaro SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. You can read more about what a GP can and can't prescribe for weight management and, if you're curious about the online consultation route, our page on accessing Mounjaro online explains how the clinical review works in practice.

Cost is a real consideration on the private route. Eli Lilly raised Mounjaro's UK list price significantly from September 2025, and typical private prices now range roughly £149–£375 per month depending on dose and provider. Our Mounjaro cost guide breaks down what's included in quoted prices and what's often left out.

Before you decide: what the clinical evidence actually says

It's worth knowing why you're having this conversation at all. Tirzepatide works differently from older weight-loss medicines: as a dual GIP and GLP-1 receptor agonist, it acts on two gut-hormone pathways involved in appetite regulation and blood-sugar control, the only licensed weight-loss treatment in the UK to do so. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants at the highest dose saw an average body-weight reduction of around 20–21% over 72 weeks. That's a meaningful number for a medicine taken once a week.

NICE recommended tirzepatide for NHS use in December 2024 (TA1026) on the basis of that evidence, which is why the phased rollout is happening at all. For eligible patients, the NHS route is real. For those outside the current thresholds, the private route offers access to the same licensed medicine, assessed by the same standard of clinical rigour. The question of which path suits you depends on your individual circumstances, which is exactly what a consultation is for. If you'd like to explore whether you might be eligible, you're welcome to speak to our prescribers through a free online consultation.

If you're also curious about how tirzepatide compares with newer medicines being investigated, our comparison of retatrutide and Mounjaro covers what's known so far, and if you're already on tirzepatide and wondering about next steps, our guide on whether you can switch from tirzepatide to retatrutide explains what the evidence currently suggests.